Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher W Ryan

Showing results (61-70 of 113) with videos related to

Pageof 12
Sort By:
Pediatric Blood & Cancer|September 28, 2012
Overcoming autopsy barriers in pediatric cancer researchJennifer L Alabran, Jody E Hooper, Melissa Hill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2025
Ribociblib in Sequential Combination with Doxorubicin in Anthracycline-Naive Advanced Soft Tissue Sarcomas: Results of a Dose-Finding Phase 1B StudyLara E Davis, Limin Zhu, Emile Latour, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)Sandip P Patel, Megan Othus, Young K Chae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
Clinical Genitourinary Cancer|October 1, 2008
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer, Bryan Goldman, Timothy W Synold, et al.
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
Tomography (Ann Arbor, Mich.)|January 10, 2017
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance ImagingWei Huang, Brooke R Beckett, Alina Tudorica, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Cancer|April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohortSandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Pageof 12

Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Pediatric Blood & Cancer|September 28, 2012
Overcoming autopsy barriers in pediatric cancer researchJennifer L Alabran, Jody E Hooper, Melissa Hill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2025
Ribociblib in Sequential Combination with Doxorubicin in Anthracycline-Naive Advanced Soft Tissue Sarcomas: Results of a Dose-Finding Phase 1B StudyLara E Davis, Limin Zhu, Emile Latour, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)Sandip P Patel, Megan Othus, Young K Chae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
Clinical Genitourinary Cancer|October 1, 2008
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer, Bryan Goldman, Timothy W Synold, et al.
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
Tomography (Ann Arbor, Mich.)|January 10, 2017
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance ImagingWei Huang, Brooke R Beckett, Alina Tudorica, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Cancer|April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohortSandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Pageof 12